NCT05565573View on ClinicalTrials.gov

Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

July 1, 2024

Study Completion Date

November 1, 2025

Conditions
Fertility Sparing
Interventions
DRUG

Medroxyprogesterone Acetate 500 MG Oral Tablet

500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate At a dosage of 500 mg/day

DEVICE

Levonorgestrel-Releasing Intrauterine System

Uterine cavity insertion

Trial Locations (1)

100025

RECRUITING

Bei Jing Chao-Yang Hospital, Beijing

All Listed Sponsors
lead

Hua Li

OTHER